Clinical Trial

A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults

Study acronym: RUBY
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of repeated administrations of AVX70371 in healthy participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-23; most recent amendment 2026-04-17.
Status change: Recruiting → Active, Not Recruiting 2025-06-17
Trial Details
NCT Number NCT06989788
Lead Sponsor AstriVax Therapeutics
Conditions Chronic Hepatitis b
Enrollment 16 participants
Start Date 2025-05-06
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-20